Skip To Main Content
Peiying Hua on Muck Rack

Peiying Hua

As seen in: Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peiying

Contact Peiying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials

|
By Jason Q. Core, Maxwell Pistilli, Peiying Hua, Ebenezer Daniel
| Texas Medical Center
PURPOSE: To describe predominantly persistent intraretinal fluid (PP-IRF) and its association with visual acuity (VA) and retinal anatomic findings at long-term follow-up in eyes treated with pro re nata (PRN) ranibizumab or bevacizumab for neovascular age-related macular degeneration. DESIGN: Cohort within a randomized clinical trial. PARTICIPANTS: Participants in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) assigned to PRN treatment.
Open in Who Shared Issue with article?

Thiazolidinedione Use and Retinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials

|
By Jason Q. Core, Peiying Hua, Ebenezer Daniel, Juan E. Grunwald
| Texas Medical Center
BACKGROUND: Thiazolidinediones, commonly used antidiabetic medications, have been associated with an increased risk of development of diabetic macular oedema and increased vascular endothelial cell permeability. Macular neovascularisation in age-related macular degeneration (AMD) and associated fluid leakage may be influenced by thiazolidinediones.
Open in Who Shared Issue with article?

Prediction for Two-Year Vision Outcomes Using Early Morphological and Functional Responses in the Comparison of AMD Treatments Trials (CATT)

|
By Peiying Hua, Maureen G. Maguire, Ebenezer Daniel, Katie Xue
| ophthalmologyretina.org
To predict 2-year visual acuity (VA) responses to anti-vascular endothelial growth factor (anti-VEGF) therapy using early morphological and functional responses in patients with neovascular age-related macular degeneration (nAMD). 1185 participants with untreated active nAMD and best corrected VA (BCVA) 20/25 to 20/320 at baseline. Secondary analysis of data from participants randomized to either ranibizumab or bevacizumab and to one of three dosing regimens.
Open in Who Shared Issue with article?
See all 4 articles